| Description | meplazumab is a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia. |
| In vivo | 与对照组相比，meplazumab治疗明显提高了重症和危重症患者的出院率（p=0.006）和病情严重度（p=0.021）。meplazumab组患者转为病毒阴性的时间较对照组显著缩短（中位数3天，95%CI[1.5-4.5]对比13天，[6.5-19.5]；p=0.014, HR=0.37, 95%CI[0.155-0.833]）。在meplazumab组中，患者恢复到正常淋巴细胞计数和CRP浓度的百分比也显著并迅速增加。在接受meplazumab治疗的患者中未发现不良效应。解释：Meplazumab在保持良好安全性档案的同时，有效促进了SARS-CoV-2肺炎患者的恢复。 |
| molecular weight | N/A |
| CAS | 2413715-21-4 |
| Storage | store at -20°C |
| References | 1. Huijie Bian, Zhao-Hui Zheng, Ding Wei,et al.Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial.bioRxiv.2020. |